[go: up one dir, main page]

PE20010110A1 - 1,5-BENZODIAZEPINE DERIVATIVES AS AGONISTS OF CCK-A RECEPTORS - Google Patents

1,5-BENZODIAZEPINE DERIVATIVES AS AGONISTS OF CCK-A RECEPTORS

Info

Publication number
PE20010110A1
PE20010110A1 PE2000000415A PE0004152000A PE20010110A1 PE 20010110 A1 PE20010110 A1 PE 20010110A1 PE 2000000415 A PE2000000415 A PE 2000000415A PE 0004152000 A PE0004152000 A PE 0004152000A PE 20010110 A1 PE20010110 A1 PE 20010110A1
Authority
PE
Peru
Prior art keywords
cck
agonists
receptors
benzodiazepine derivatives
phenyl
Prior art date
Application number
PE2000000415A
Other languages
Spanish (es)
Inventor
David Colclough
Jerzy Ryszard Szewczyk
Anne Hodgson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910366.5A external-priority patent/GB9910366D0/en
Priority claimed from GBGB0008179.4A external-priority patent/GB0008179D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20010110A1 publication Critical patent/PE20010110A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A EL ACIDO 3-{3-[1-(ISOPROPIL-FENIL-CARBAMOILMETIL)-2,4-DIOXO-5-FENIL-2,3,4,5-TETRAHIDRO-1H-BENZO[b][1,4]DIAZEPIN-3-IL]UREIDO}BENZOICO ENANTIOMERICAMENTE ENRIQUECIDO ACEPTABLE Y SE CARCATERIZA POR SER AL MENOS EL 90% DEL COMPUESTO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION Y A COMPUESTOS INTERMEDIOS. EL COMPUESTO I ACTUA COMO AGONISTA DE RECEPTORES DE COLECISTOCININA CCK-A Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA OBESIDAD, ESTASIS DE LA VESICULA BILIAR, DIABETESREFERS TO THE ACID 3- {3- [1- (ISOPROPYL-PHENYL-CARBAMOylmethyl) -2,4-DIOXO-5-PHENYL-2,3,4,5-TETRAHYDRO-1H-BENZO [b] [1, 4] DIAZEPIN-3-IL] UREIDO} BENZOIC ENANTHIOMERICALLY ENRICHED ACCEPTABLE AND CHARACTERIZED AS BEING AT LEAST 90% OF THE COMPOUND. IT ALSO REFERS TO A PROCEDURE FOR THE PREPARATION AND TO INTERMEDIATE COMPOUNDS. COMPOUND I ACTS AS A RECEPTOR AGONIST FOR CHOLECYSTOCININ CCK-A AND MAY BE USEFUL FOR THE TREATMENT OF OBESITY, BILIARY BLADDER, DIABETES

PE2000000415A 1999-05-06 2000-05-04 1,5-BENZODIAZEPINE DERIVATIVES AS AGONISTS OF CCK-A RECEPTORS PE20010110A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9910366.5A GB9910366D0 (en) 1999-05-06 1999-05-06 1,5-Benzodiazepine Derivatives
GBGB0008179.4A GB0008179D0 (en) 2000-04-05 2000-04-05 Chemical process

Publications (1)

Publication Number Publication Date
PE20010110A1 true PE20010110A1 (en) 2001-03-05

Family

ID=26244033

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000415A PE20010110A1 (en) 1999-05-06 2000-05-04 1,5-BENZODIAZEPINE DERIVATIVES AS AGONISTS OF CCK-A RECEPTORS

Country Status (21)

Country Link
EP (1) EP1212305A2 (en)
JP (1) JP2002544200A (en)
KR (1) KR20020012567A (en)
CN (1) CN1161345C (en)
AR (1) AR022044A1 (en)
AU (1) AU4754800A (en)
BR (1) BR0010338A (en)
CA (1) CA2370801A1 (en)
CO (1) CO5170461A1 (en)
CZ (1) CZ20013988A3 (en)
HK (1) HK1046138A1 (en)
HU (1) HUP0201181A3 (en)
IL (1) IL146124A0 (en)
MX (1) MXPA01011267A (en)
MY (1) MY138319A (en)
NO (1) NO20015397L (en)
NZ (1) NZ515048A (en)
PE (1) PE20010110A1 (en)
PL (1) PL351546A1 (en)
TR (1) TR200103169T2 (en)
WO (1) WO2000068209A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035793A2 (en) * 2003-10-09 2005-04-21 Decode Genetics Ehf. Cckar markers and haplotypes associated with extreme weight conditions
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
MX2022004142A (en) 2019-10-07 2022-09-21 Kallyope Inc Gpr119 agonists.
TW202140440A (en) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40 agonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9307833D0 (en) * 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin

Also Published As

Publication number Publication date
MXPA01011267A (en) 2002-05-06
NO20015397D0 (en) 2001-11-05
WO2000068209A3 (en) 2001-03-01
HUP0201181A3 (en) 2003-10-28
IL146124A0 (en) 2002-07-25
AR022044A1 (en) 2002-09-04
HUP0201181A2 (en) 2002-12-28
NO20015397L (en) 2001-11-05
AU4754800A (en) 2000-11-21
CA2370801A1 (en) 2000-11-16
EP1212305A2 (en) 2002-06-12
BR0010338A (en) 2002-02-13
TR200103169T2 (en) 2002-04-22
JP2002544200A (en) 2002-12-24
MY138319A (en) 2009-05-29
CO5170461A1 (en) 2002-06-27
CN1161345C (en) 2004-08-11
NZ515048A (en) 2004-01-30
PL351546A1 (en) 2003-05-05
KR20020012567A (en) 2002-02-16
CZ20013988A3 (en) 2002-02-13
WO2000068209A2 (en) 2000-11-16
CN1362949A (en) 2002-08-07
HK1046138A1 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
AR006545A1 (en) SUBSTITUTE COMPOUNDS FOR CATECOLAMINS, USEFUL AS BETA3 ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATE COMPOUNDS FOR EXCLUSIVE APPLICATION IN THE PREPARATION OF SUCH COMPOUNDS
PE20081557A1 (en) SUBSTITUTE OXINDOL DERIVATIVES, DRUGS THAT UNDERSTAND THEM, AND THE USE OF THEM
Robertson et al. Structure-activity relationships of (arylalkyl) imidazole anticonvulsants: comparison of the (fluorenylalkyl) imidazoles with nafimidone and denzimol
MY143834A (en) Thrombin receptor antagonists
UY26291A1 (en) CHEMICAL COMPOUNDS XXII
BR0013427A (en) Heteropolyclic Compounds and Their Uses as Metabotropic Glutamate Receptor Antagonists
PE20040600A1 (en) TRIAZOLE DERIVATIVES AS ANTAGONISTS OF THE TACHYCININ RECEPTOR
PE20020082A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1)
MXPA03001073A (en) Compounds acting as melanocortin receptor ligands.
IE53016B1 (en) Benzazepines and benzodiazepines
EP1413576A3 (en) Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
NO20032161L (en) Tetrahydrobenzazepine derivatives for use as modulators of dopamine D3 receptor (antipsychotic agents)
BG106142A (en) Glucocorticoid receptor modulators
PE20060627A1 (en) CONDENSED PIRAZOLE DERIVATIVES AS AGONISTS OF CANNABINOID RECEPTORS CB1 AND / OR CB2
PE86499A1 (en) 2- (R) - (1- (R) -3,5-BIS (TRIFLUOROMETIL) -PHENYL) ETOXI) -3- (S) - (4-FLUORINE) FENYL-4- (3- (5) -OXO-1H, 4H-1,2,4-TRIAZOLE) METHYLMORFOLIN USEFUL AS A TACHYQUININE RECEPTOR ANTAGONIST
NZ598064A (en) Benzazepine derivatives useful as vasopressin antagonists
ZA908508B (en) Substituted 5-((tetrazolyl)alkenyl)imidazoles
PE20011114A1 (en) DECAHYDRO-ISOQUINOLINS
IL190219A (en) Compounds which have activity at m1 receptor, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments
AR033377A1 (en) DERIVATIVES OF BENZOCICLOALQUILENILAMINA AS ANTAGONISTS OF MUSCARINIC RECEPTORS
PE20010110A1 (en) 1,5-BENZODIAZEPINE DERIVATIVES AS AGONISTS OF CCK-A RECEPTORS
NO322571B1 (en) Condensed azepines as vasopressin agonists
Wrobleski et al. Cyclobutane derivatives as potent NK1 selective antagonists
TW200602024A (en) Constrained himbacine analogs as thrombin receptor antagonists
ES2178717T3 (en) USE OF LEVO ENANTIOMERS OF MEDETOMIDINE DERIVATIVES.

Legal Events

Date Code Title Description
FC Refusal